Potential Implementation of Rabeprazole in prevention of Acidity in GIT: Short Statement
DOI:
https://doi.org/10.22270/ajprd.v14i5.1858Abstract
Rabeprazole is a proton pump inhibitor. Pharmacodynamic data show rabeprazole can achieve optimal acid suppression since the first administration and can maintain this advantage in the following days of therapy. Moreover, rabeprazole has the highest pKa (~ 5.0, the pH at which a drug becomes 50% protonated), and hence the molecule can be activated at higher pH levels much faster than other PPIs. Due to its peculiar catabolic pathway, ie, a prevalent metabolism through a non-enzymatic pathway, rabeprazole is less susceptible to the influence of genetic polymorphisms for CYP2C19, resulting in minor influences on its pharmacokinetics and pharmacodynamics. To prevent symptomatic relapse, on-demand strategy with rabeprazole 10 mg daily appears to be ideal, due to its rapidity of onset; results on NERD patients have documented its superiority over placebo. Continuous treatment, however, up to 5 years, seems to achieve better results than on-demand therapy, particularly in patients with esophagitis. It is debated whether in the latter halved doses (10 mg) are really equivalent to full dose (20 mg). Finally, rabeprazole achieves similar Helicobacter pylori eradication rates compared with omeprazole and pantoprazole when co-administrated with low or high doses of antibiotics (amoxicillin and clarithromycin). In addition, low doses of rabeprazole (10 mg/bid) may be effective in eradicating the pathogen.
Downloads
References
Adachi K, Hashimoto T, Hamamoto N, et al. 2013. Symptom relief in patients with refl2ux sophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole. J GastroenterolHepatol, 18:1392–8.
Adachi K, Katsube T, Kawamura A, et al. 2010. CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole. Aliment PharmacolTher, 14:1259-66.
Ando T, Kato H, Sugimoto N, et al. 2015. A comparative study on endoscopic ulcer healing of omeprazole versus rabeprazole with respect to CYP2C19 genotypic differences. Dig Dis Sci, 50:1625–31.
Archimandritis AJ, Nikolopoulou V, Kouklakis G, et al. 2005. Effects of rabeprazole on early symptom relief in gastro-oesophageal reflux disease: the Hellenic Rabeprazole Study Group surveillance study. Curr Med Res Opin, 21:603–10.
Barth J, Perdomo C, Sloan S. 1999. Rabeprazole maintains GERD healing in patients with Barrett’s esophagus. Am J Gastroenterol, 94:2579.
Bell NJ, Burget D, Howden CW, et al. 1992. Appropriate acid suppression for the management of gastro-oesophagealreflux disease. Digestion, 51(Suppl 1):59–67.
Besancon M, Simon A, Sachs G, et al. 1997. Sites of reaction of the gastric H,K-ATPase with extra cytoplasmicthiol reagents. J BiolChem, 272:22438–46.
Birbara C, Breiter J, Perdomo C, et al. 2000. Rabeprazole for the prevention of recurrent erosive or ulcerative gastro-oesophagealreflux disease. Rabeprazole Study Group. Eur J GastroenterolHepatol, 12:889–97.
Bour B, Staub JL, Chousterman M, et al. 2005. Long-term treatment of gastro-oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole: on-demand treatment compared with continuous treatment. Aliment PharmacolTher, 21:805–12.
Bruley Des Varannes S, Gharib H, Bicheler V, et al. 2004. Effect of lowdoserabeprazole and omeprazole on gastric acidity: results of a double blind, randomized, placebo-controlled, three-way crossover study in healthy subjects. Aliment PharmacolTher, 20:899–907.
Burget DW, Chiverton SG, Hunt RH. 1990. Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression. Gastroenterology, 99:345–51.
Dickman R, Emmons S, Cui H, et al. 2005. The effect of a therapeutic trial of high-dose rabeprazole on symptom response of patients with noncardiac chest pain: a randomized, double-blind, placebo-controlled, crossover trial. Aliment PharmacolTher, 22:547–55.
Dubois D, Hughes DA, Bodger K, et al. 2005. Economic analysis of ondemand maintenance therapy with proton pump inhibitors in patients with non-erosive reflux disease. Pharmacoeconomics, 23:1031–41.
Farley A, Wruble LD, Humphries TJ. 2000. Rabeprazole versus ranitidine for the treatment of erosive gastro esophageal reflux disease: a doubleblind, randomized clinical trial. Raberprazole Study Group. Am J Gastroenterol, 95:1894–9.Fass R, Ofman JJ. 2002.
Gastroesophageal reflux disease: should we adopt a new conceptual framework? Am J Gastroenterol, 97:1901–9. Feldman M, Burton ME. 1990. Histamine H2-receptor antagonists. N Engl J Med, 323:1672–80.
Fletcher J, Wirz A, Young J, Vallance R, McColl KE. 2001. Unbuffered highly acidic gastric juice exists at the gastroesophageal junction after a meal. Gastroenterology, 121:775–83.
Fock KM, Teo EK, Ang TL, et al. 2005. Rabeprazolevs esomeprazole in non-erosive gastro-esophageal reflux disease: a randomized, doubleblind study in urban Asia. World J Gastroenterol, 11:3091–8. Fuhr U, Jetter A. 2002.
Rabeprazole: pharmacokinetics and pharmacokinetic drug interactions. Pharmazie, 57:595–601.
Furuta T, Shirai N, Sugimoto M, et al. 2005. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug MetabPharmacokinet, 20:153–67.
Gambaro C, Bilardi C, Dulbecco P, et al. 2003.Comparable Helicobacter pylori eradication rates obtained with 4- and 7-day rabeprazole-based triple therapy: a prelimary study. Dig Liv Dis, 35:763–7.
Gardner JD, Gallo-Torres H, Sloan S, et al. 2003. The basis for the decreased response to proton pump inhibitors in gastro-oesophagealreflux disease patients without erosive oesophagitis. Aliment PharmacolTher, 18:891–905.
Gerson LB, Shetler K, Triadafilopoulos G. 2005. Control of intra-oesophageal and intra-gastric pH with proton pump inhibitors in patients with Barrett’s oesophagus. Dig Liv Dis, 37:651–8.
Warrington S, Baisley K, Boyce M, et al. 2002. Effects of rabeprazole 20 mg, or esomeprazole 20 mg, on 24-h intragastric pH and serum gastrin in healthy subjects. Aliment PharmacolTher, 16:1301–7. Williams MP, Sercombe J, Hamilton MI, et al. 1998.
A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment PharmacolTher, 12:1079–89.
Published
How to Cite
Issue
Section
Copyright (c) 2026 Ravi Kumar, Abhinay Gupta, Yogesh Kumar Yadav, Surjeet Singh, Sachin Kumar Yadav, Madhu Sharma, Vishu Jain, Abhimanyu Kumar, Riddhi Malhotra, Parveen Kumar

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
.